The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC by Patil, Tejas, MD, Staley, Alyse, MS, Nie, Yunan, MD, Sakamoto, Mandy, MD, Stalker, Margaret, MD, Jurica, James M., MD, MBA, Koehler, Kenna, BA, Cass, Amanda, PharmD, Kuykendall, Halle, BA, Schmitt, Emily, MS, Filar, Emma, BA, Reventaite, Evelina, MS, Davies, Kurt D., PhD, Nijmeh, Hala, PhD, Haag, Mary, PhD, Yoder, Benjamin A., PharmD, Bunn, Paul A., MD, Schenk, Erin L., MD, PhD, Aisner, Dara L., MD, PhD, Iams, Wade T., MD, Marmarelis, Melina E., MD, Camidge, D. Ross, MD, PhD

Get full text